FIRST-EVER, 36-MONTH REAL-WORLD, POST-MARKETING SURVEILLANCE STUDY FOR IBgard®, A NONPRESCRIPTION PRODUCT FOR IRRITABLE BOWEL SYNDROME, NOW PEER-REVIEWED AND NOW ACCEPTED FOR POSTER PRESENTATION AT UPCOMING DDW®, THE WORLD’S PREMIER GASTROENTEROLOGY CONFERENCE
Source: IBgardPublished on 2020-02-13